The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $6.81

Today's change+0.15 +2.25%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $6.81

Today's change+0.15 +2.25%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc up sharply

ARIAD Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$0.15 or 2.25% to (U.S.)$6.81. Over the last five days, shares have gained 7.08%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 17.78% during the last year.

Key company metrics

  • Open(U.S.) $6.66
  • Previous close(U.S.) $6.66
  • High(U.S.) $6.85
  • Low(U.S.) $6.60
  • Bid / Ask-- / --
  • YTD % change-0.15%
  • Volume2,807,829
  • Average volume (10-day)7,291,667
  • Average volume (1-month)7,491,674
  • Average volume (3-month)6,954,139
  • 52-week range(U.S.) $4.90 to (U.S.) $9.83
  • Beta1.41
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.24
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-492.24%

ARIAD Pharmaceuticals Inc has a net profit margin of -492.24%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1512128
Total other revenue--------
Total revenue1512128
Gross profit1410100
Total cost of revenue1219
Total operating expense62686182
Selling / general / administrative34343238
Research & development28322936
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-47-56-50-74
Interest income (expense), net non-operating-4-100
Gain (loss) on sale of assets--------
Other--------
Income before tax-50-57-50-74
Income after tax-50-57-50-74
Income tax, total0000
Net income-50-57-50-74
Total adjustments to net income--------
Net income before extra. items-50-57-50-74
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-50-57-50-74
Inc. avail. to common incl. extra. items-50-57-50-74
Diluted net income-50-57-50-74
Dilution adjustment0000
Diluted weighted average shares187187186186
Diluted EPS excluding extraordinary itemsvalue per share-0.27-0.30-0.27-0.40
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.27-0.30-0.27-0.40